Companies: 10,795·Total market cap: $144.5T
Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.

AVTXNASDAQHealthcare● Active
$12.74
$-0.36(-2.75%)
Market Cap$143887051
P/E Ratio
52W High$24.27
52W Low$4.06
Overview

Avalo Therapeutics, Inc. (AVTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AVTX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-5.83avtx eps ttm · avtx earnings per shareEarnings history
PE Ratio (TTM)avtx pe ratio ttm · avtx price to earningsPE Ratio deep dive
Revenue (TTM)59000.00avtx revenue ttm · avtx annual revenueFull revenue history
Dividend YieldNo Dividenddoes avtx pay dividends · avtx dividend yieldDividend history
Shares Outstanding13.4Mavtx shares outstanding · avtx floatShares outstanding history
Next EarningsAug 6, 2026Est.avtx earnings date · avtx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$59000.00▼ 86.62% YoY
202320242025
avalo therapeutics, inc. revenue · avtx revenue 2025
FY 2025Net Income-$78.3M▼ 122.78% YoY
202320242025
avalo therapeutics, inc. net income · avtx profit 2025
FY 2025EPS$-5.84▼ 35.19% YoY
202320242025
avtx eps · avalo therapeutics, inc. earnings per share 2025
TTM:Revenue: $59000.00Net Income: -$84.7MEPS: $-5.83View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy9 analystsis avtx a buy · avtx analyst rating
Strong Buy
0
Buy
7
Hold
1
Sell
1
Strong Sell
0
12-Month Price Target
$34.00Low
$12.74Current
$47.14Avg Target270.02% upside
$60.00High
avtx price target · avtx 12 month forecast

Total: 9 · Buy rate: 77.8%

The AVTX analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $47.14, representing +270.02% upside from the current price of $12.74.

Stock Performance

Full History
1D-0.80%
1W-8.49%
1M-39.76%
3M-24.93%
YTD-28.44%
1Y+184.97%
5Y-99.86%

About Avalo Therapeutics, Inc.

CEOGarry A. Neil
IPO DateOct 14, 2015
Employees23
CountryUS

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical…

what is avalo therapeutics, inc. · avtx stock overview · avalo therapeutics, inc. company profile · who is avalo therapeutics, inc. ceo · avtx NASDAQ · avalo therapeutics, inc. headquarters · avalo therapeutics, inc. business segments

About Stock Overview & Key Data

Avalo Therapeutics, Inc. (AVTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 14, 2015. As of the latest trading session, AVTX stock price is $12.74, with a market capitalization of $143.9M. The stock has returned +184.97% over the past 12 months and -28.44% year-to-date.

According to 9 Wall Street analysts, the consensus rating for Avalo Therapeutics, Inc. stock is Buy, with an average 12-month price target of $47.14. In fiscal year 2025, Avalo Therapeutics, Inc. reported revenue of $59000.00 and net income of -$78.3M. For detailed data — including Avalo Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Avalo Therapeutics, Inc. (AVTX) stock price is $12.74. The stock is traded on NASDAQ under the ticker symbol AVTX. The 52-week range is $4.06 – $24.27.

AVTX stock priceAVTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice